Sat, Dec 27, 2014, 4:09 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Uranium Energy Corp. Message Board

nj46nick 76 posts  |  Last Activity: Dec 24, 2014 9:30 AM Member since: Feb 1, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • nj46nick by nj46nick Dec 24, 2014 9:30 AM Flag

    Are they working for you on the yahoo board? Thanks

    Sentiment: Strong Buy

  • Reply to

    Merry Christmas!!!

    by thunderstormmm Dec 24, 2014 8:52 AM
    nj46nick nj46nick Dec 24, 2014 9:00 AM Flag

    Merry Christmas!!! Thank You!

    Sentiment: Strong Buy

  • Reply to

    This has to be the ugliest board on yahoo

    by whatsarfweslh Dec 24, 2014 7:52 AM
    nj46nick nj46nick Dec 24, 2014 8:17 AM Flag

    You would not believe how many bashers I have on iggy. My board for the most part is basically clean! Have a great day! Our day is getting closer!

    Sentiment: Strong Buy

  • Reply to

    Lympro

    by watsonhelper Dec 23, 2014 7:44 AM
    nj46nick nj46nick Dec 23, 2014 8:40 AM Flag

    Thank You for all your input! Wish you the very best for the New Year!

    Sentiment: Strong Buy

  • Reply to

    Lympro

    by watsonhelper Dec 23, 2014 7:44 AM
    nj46nick nj46nick Dec 23, 2014 8:38 AM Flag

    Likewise!

    Sentiment: Strong Buy

  • nj46nick by nj46nick Dec 22, 2014 7:03 AM Flag

    Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials

    Sentiment: Strong Buy

  • DO SOME INVESTIGATING. I CAN'E TYPE THEM HERE! Most recent in the news.... The flu here in the U.S. and there is cause for concern regarding antibiotic over in India. I am getting sick of the M.B's. The ruler allows only certain things to type here. Have a good weekend.

    Sentiment: Strong Buy

  • nj46nick by nj46nick Dec 19, 2014 7:46 AM Flag

    Company News
    Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
    Download PDF
    SAN FRANCISCO and GENEVA, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.

    MANF, a naturally-occurring protein that reduces and prevents apoptosis (programmed cell death) in response to injury or disease, was discovered utilizing Amarantus' proprietary PhenoGuardTM Protein Discovery Engine. Pre-clinical data showed that MANF provided protective functional effects in an animal model of RAO. Moreover, toxicology studies have demonstrated that MANF was well-tolerated following a single intravitreal administration of a therapeutically relevant dose.

    "Filing our second Orphan Drug Designation for MANF is an important component of our regulatory strategy for the program," said Gerald E. Commissiong, President & CEO of Amarantus. "We believe that our pre-clinical efficacy data with MANF supports its use in ophthalmologic disorders such as RAO and retinitis pigmentosa (orphan status applied for in October 2014) where there are currently limited or no treatment options available. We are extremely encouraged by our data and believe MANF has the potential to provide meaningful changes to the quality of life of patients and their families."

    The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.

    About Retinal Artery Occlusion

    Retinal artery occlusion (RAO) is a rare eye condition caused by a loss of blood supply to the inner layer of the retina resulting in acute and often severe vision loss. RAO is further classified as central or branch retinal artery occlusion, respectively, depending on the location of the occlusion. The currently-available treatments are aimed at opening the occluded artery before irreversible damage occurs and most often do not improve visual acuity above natural history. There are no effective neuroprotective agents for the treatment of acute retinal ischemia available. The prevalence for RAO is approximately 10,450 patients in the United States.

    About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

    MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics.

    MANF's lead indication is retinitis pigmentosa, and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are currently pursued. Further applications for MANF may include Alzheimer's disease, traumatic brain injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation.

    Sentiment: Strong Buy

  • nj46nick by nj46nick Dec 19, 2014 7:18 AM Flag

    Amarantus Announces Second Closing of Series E Preferred Financing
    Amarantus BioScience Holdings, Inc.
    17 minutes ago
    GlobeNewswire
    
    SAN FRANCISCO and GENEVA, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has entered into definitive agreements to raise an additional $2.0 million under its previously announced transaction to issue shares of Series E Preferred Stock (the "Series E"), bringing the total capital raised to $5.0 million. The second closing was led by International Infusion.

    "In recent months, we have been working towards further strengthening our balance sheet, and I am very pleased to have the ability to both extend our cash runway and facilitate the expansion of our product portfolio," commented Gerald E. Commissiong, President and CEO of Amarantus. "Our goal is to continue to prepare Amarantus for a transformational 2015, and I believe we are positioned to achieve this."

    The Series E is convertible into Amarantus common stock at a price of $0.08 per share, subject to proportional adjustment for stock splits. No warrants were issued in connection with the Series E, and all of the investors have agreed to a "no shorting" provision. Further, the common shares underlying the Series E cannot be sold into the market for 6 months. The additional funds are expected to be used for general corporate purposes, to facilitate the company's previously announced exclusive option agreement with Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd., to acquire Cutanogen Corporation, a subsidiary of Lonza Walkersville, to develop ESS-W, an autologous skin replacement product for the treatment of Stage 3 and Stage 4 full thickness severe burns, to advance its therapeutic clinical development programs, as well as execute potential business development opportunities.

    Sentiment: Strong Buy

  • Double blow for Roche as Alzheimer's, breast cancer studies fail

    Sentiment: Strong Buy

  • Reply to

    Excellent explanation!

    by nj46nick Dec 18, 2014 6:30 AM
    nj46nick nj46nick Dec 18, 2014 6:41 AM Flag

    More info.... This market pulse title...Thoughts on $ECIG EOD close? Buyout thoughts? 12/14/14 4:28 pm.then go down to 9:03 pm. BriOn H. Can't put too certain things on here!

    Sentiment: Strong Buy

  • Check it out on market pulse,BriOnH, go down to last reply ,12/17/14 @ 9:03

    Sentiment: Strong Buy

  • Reply to

    50 cents

    by krw62 Dec 17, 2014 9:11 AM
    nj46nick nj46nick Dec 17, 2014 9:15 AM Flag

    Some body is playing!

  • Reply to

    bill signed

    by nj46nick Dec 17, 2014 4:22 AM
    nj46nick nj46nick Dec 17, 2014 7:00 AM Flag

    Spread the word, tw,fb, etc.

    Sentiment: Strong Buy

  • nj46nick by nj46nick Dec 17, 2014 4:22 AM Flag

    Obama signs $1.1 trillion spending bill into law

    Sentiment: Strong Buy

  • Reply to

    seeking alpha instablog just came out!

    by grailhunter Dec 16, 2014 4:39 PM
    nj46nick nj46nick Dec 16, 2014 4:53 PM Flag

    Nice!

    Sentiment: Strong Buy

  • Reply to

    WOW!!!!!

    by nj46nick Dec 16, 2014 12:35 PM
    nj46nick nj46nick Dec 16, 2014 1:34 PM Flag

    I believe so!

    Sentiment: Strong Buy

  • nj46nick by nj46nick Dec 16, 2014 12:35 PM Flag

    THERE SHE GOES!!!!!

    Sentiment: Strong Buy

  • Reply to

    This was just put out there. Good news!

    by nj46nick Dec 15, 2014 6:31 PM
    nj46nick nj46nick Dec 15, 2014 7:07 PM Flag

    If it goes lower... I'll buy a ton more! Best to ya!

    Sentiment: Strong Buy

  • Reply to

    This was just put out there. Good news!

    by nj46nick Dec 15, 2014 6:31 PM
    nj46nick nj46nick Dec 15, 2014 7:06 PM Flag

    no where to go but up from here!

    Sentiment: Strong Buy

UEC
1.67-0.04(-2.34%)Dec 26 4:02 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST
Thor Industries Inc.
NYSEFri, Dec 26, 2014 4:09 PM EST